Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T99740
(Former ID: TTDC00022)
|
|||||
| Target Name |
Myb messenger RNA (MYB mRNA)
|
|||||
| Synonyms |
Transcriptional activator Myb (mRNA); Proto-oncogene c-Myb (mRNA)
Click to Show/Hide
|
|||||
| Gene Name |
MYB
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Malignant haematopoietic neoplasm [ICD-11: 2B33] | |||||
| Function |
Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells. Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'.
Click to Show/Hide
|
|||||
| BioChemical Class |
mRNA target
|
|||||
| UniProt ID | ||||||
| Sequence |
MARRPRHSIYSSDEDDEDFEMCDHDYDGLLPKSGKRHLGKTRWTREEDEKLKKLVEQNGT
DDWKVIANYLPNRTDVQCQHRWQKVLNPELIKGPWTKEEDQRVIELVQKYGPKRWSVIAK HLKGRIGKQCRERWHNHLNPEVKKTSWTEEEDRIIYQAHKRLGNRWAEIAKLLPGRTDNA IKNHWNSTMRRKVEQEGYLQESSKASQPAVATSFQKNSHLMGFAQAPPTAQLPATGQPTV NNDYSYYHISEAQNVSSHVPYPVALHVNIVNVPQPAAAAIQRHYNDEDPEKEKRIKELEL LLMSTENELKGQQVLPTQNHTCSYPGWHSTTIADHTRPHGDSAPVSCLGEHHSTPSLPAD PGSLPEESASPARCMIVHQGTILDNVKNLLEFAETLQFIDSFLNTSSNHENSDLEMPSLT STPLIGHKLTVTTPFHRDQTVKTQKENTVFRTPAIKRSILESSPRTPTPFKHALAAQEIK YGPLKMLPQTPSHLVEDLQDVIKQESDESGIVAEFQENGPPLLKKIKQEVESPTDKSGNF FCSHHWEGDSLNTQLFTQTSPVADAPNILTSSVLMAPASEDEDNVLKAFTVPKNRSLASP LQPCSSTWEPASCGKMEEQMTSSSQARKYVNAFSARTLVM Click to Show/Hide
|
|||||
| HIT2.0 ID | T18CWB | |||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | LR3001 | Drug Info | Phase 2 | Myeloid leukaemia | [2] | |
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| KEGG Pathway | [+] 2 KEGG Pathways | + | ||||
| 1 | PI3K-Akt signaling pathway | |||||
| 2 | HTLV-I infection | |||||
| NetPath Pathway | [+] 2 NetPath Pathways | + | ||||
| 1 | TCR Signaling Pathway | |||||
| 2 | IL2 Signaling Pathway | |||||
| PID Pathway | [+] 5 PID Pathways | + | ||||
| 1 | IL4-mediated signaling events | |||||
| 2 | IL2 signaling events mediated by PI3K | |||||
| 3 | AP-1 transcription factor network | |||||
| 4 | C-MYB transcription factor network | |||||
| 5 | Notch-mediated HES/HEY network | |||||
| Reactome | [+] 1 Reactome Pathways | + | ||||
| 1 | Factors involved in megakaryocyte development and platelet production | |||||
| WikiPathways | [+] 6 WikiPathways | + | ||||
| 1 | SIDS Susceptibility Pathways | |||||
| 2 | EV release from cardiac cells and their functional effects | |||||
| 3 | Hematopoietic Stem Cell Differentiation | |||||
| 4 | Neural Crest Differentiation | |||||
| 5 | miR-targeted genes in lymphocytes - TarBase | |||||
| 6 | Factors involved in megakaryocyte development and platelet production | |||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Genta obtains orphan drug designation for C-Myb Antisense (LR3001) in chronic myelocytic leukemia. Genta. 2005. | |||||
| REF 2 | Pipeline report of Genta. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.